Eledon Pharmaceuticals, Inc. (ELDN)Healthcare | Biotechnology | Irvine, United States | NasdaqCM
3.86 USD
+0.01
(0.260%)
⇧
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 2:43 a.m. EDT
The immediate outlook is neutral, caught between defensive hedging and modest upside potential. While the stock recently rallied off clinical trial data and sits above its 200-day average, the underlying business remains in a precarious spot with negative earnings, negative free cash flow, and a massive cumulative decline over the last decade. The market has priced in significant risk, evidenced by the heavy put activity at lower strikes. There is no compelling case for a high-conviction entry here; the company is still proving its ability to generate sustainable revenue and profits, making it a speculative hold rather than a core investment. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.069281 |
| AutoARIMA | 0.074225 |
| AutoETS | 0.074225 |
| AutoTheta | 0.087165 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 40% |
| H-stat | 1.14 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.143 |
| Excess Kurtosis | -0.72 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.552 |
| Market Cap | 297,944,992 |
| Forward P/E | -5.34 |
| Beta | 0.96 |
| Previous Name | Novus Therapeutics, Inc. |
| Website | https://eledon.com |
As of July 11, 2026, 2:43 a.m. EDT: Speculators are positioning defensively with heavy put volume at the $2.50 strike, creating a significant floor despite low implied volatility. Call interest is concentrated at the money ($5.00), suggesting a neutral-to-slightly-bullish bias for a move toward analyst targets, but the lack of deep out-of-the-money call volume indicates limited conviction in a massive breakout. The imbalance in open interest favors downside protection over aggressive upside speculation.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.0025974512 |
| Address1 | 19,800 MacArthur Boulevard |
| Address2 | Suite 250 |
| All Time High | 4,860.0 |
| All Time Low | 1.07 |
| Ask | 4.82 |
| Ask Size | 2 |
| Audit Risk | 10 |
| Average Daily Volume10 Day | 1,569,190 |
| Average Daily Volume3 Month | 1,567,947 |
| Average Volume | 1,567,947 |
| Average Volume10Days | 1,569,190 |
| Beta | 0.96 |
| Bid | 2.74 |
| Bid Size | 2 |
| Board Risk | 7 |
| Book Value | 1.322 |
| City | Irvine |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.86 |
| Current Ratio | 8.439 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 3.88 |
| Day Low | 3.75 |
| Debt To Equity | 0.552 |
| Display Name | Eledon Pharmaceuticals |
| Dividend Date | 1,601,856,000 |
| Earnings Timestamp | 1,778,702,400 |
| Earnings Timestamp End | 1,786,651,200 |
| Earnings Timestamp Start | 1,786,651,200 |
| Ebitda Margins | 0.0 |
| Enterprise Value | 187,410,992 |
| Eps Current Year | -0.8725 |
| Eps Forward | -0.72333 |
| Eps Trailing Twelve Months | -0.77 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.777 |
| Fifty Day Average Change | 0.082999945 |
| Fifty Day Average Change Percent | 0.021975098 |
| Fifty Two Week Change Percent | 0.25974512 |
| Fifty Two Week High | 4.6 |
| Fifty Two Week High Change | -0.74 |
| Fifty Two Week High Change Percent | -0.16086957 |
| Fifty Two Week Low | 1.35 |
| Fifty Two Week Low Change | 2.5099998 |
| Fifty Two Week Low Change Percent | 1.859259 |
| Fifty Two Week Range | 1.35 - 4.6 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,410,960,600,000 |
| Float Shares | 69,929,080 |
| Forward Eps | -0.72333 |
| Forward P E | -5.3364296 |
| Free Cashflow | -39,672,500 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 33 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01092 |
| Held Percent Institutions | 0.59349 |
| Implied Shares Outstanding | 77,187,823 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,601,856,000 |
| Last Split Factor | 1:18 |
| Long Business Summary | Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc.; and a strategic collaboration with NewcelX Ltd. for the development of the NCEL-101 therapy for Type 1 Diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California. |
| Long Name | Eledon Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 297,944,992 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_62494905 |
| Most Recent Quarter | 1,774,915,200 |
| Name Change Date | 2,026-07-14 |
| Net Income To Common | -78,147,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 297,944,996 |
| Number Of Analyst Opinions | 5 |
| Open | 3.8296 |
| Operating Cashflow | -68,893,000 |
| Operating Margins | 0.0 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 949 238 8090 |
| Pre Market Change | 0.010100126 |
| Pre Market Change Percent | 0.26166132 |
| Pre Market Price | 3.8701 |
| Pre Market Time | 1,784,032,789 |
| Prev Name | Novus Therapeutics, Inc. |
| Previous Close | 3.85 |
| Price Eps Current Year | -4.4240685 |
| Price Hint | 4 |
| Price To Book | 2.9198184 |
| Profit Margins | 0.0 |
| Quick Ratio | 8.298 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.00999999 |
| Regular Market Change Percent | 0.25974 |
| Regular Market Day High | 3.88 |
| Regular Market Day Low | 3.75 |
| Regular Market Day Range | 3.75 - 3.88 |
| Regular Market Open | 3.8296 |
| Regular Market Previous Close | 3.85 |
| Regular Market Price | 3.86 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 918,635 |
| Return On Assets | -0.35095 |
| Return On Equity | -0.72682 |
| Sand P52 Week Change | 0.20365608 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 77,187,823 |
| Shares Percent Shares Out | 0.1015 |
| Shares Short | 7,832,853 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 7,283,375 |
| Short Name | Eledon Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.1015 |
| Short Ratio | 4.59 |
| Source Interval | 15 |
| State | CA |
| Symbol | ELDN |
| Target High Price | 12.0 |
| Target Low Price | 7.0 |
| Target Mean Price | 9.0 |
| Target Median Price | 8.0 |
| Total Cash | 111,089,000 |
| Total Cash Per Share | 1.439 |
| Total Debt | 555,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.77 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.828775 |
| Two Hundred Day Average Change | 1.031225 |
| Two Hundred Day Average Change Percent | 0.36454827 |
| Type Disp | Equity |
| Volume | 918,635 |
| Website | https://eledon.com |
| Zip | 92,612 |